Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.73 |
| ▸ | FNTB | P49356 | 12/20 | 0.73 |
| ▸ | PGGT1B | P53609 | 12/20 | 0.73 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.42 |
| ▸ | GRN | P28799 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6782824 | 0.92 | FNTA (0.62) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL6782826 | 0.92 | FNTA (0.62) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL4280385 | 0.89 | FNTA (0.78) | FNTAFNTBPGGT1BBCL2L1TDP1 | |
| Trifluoroacetic Acid SCHEMBL1396830 | 0.84 | FNTA (0.71) | FNTAFNTBPGGT1BBCL2L1TDP1 | |
| Trifluoroacetic Acid SCHEMBL21933140 | 0.84 | FNTA (0.71) | FNTAFNTBPGGT1BBCL2L1TDP1 | |
| Trifluoroacetic Acid SCHEMBL20564403 | 0.84 | FNTA (0.71) | FNTAFNTBPGGT1BBCL2L1TDP1 | |
| Trifluoroacetic Acid SCHEMBL31561401 | 0.84 | FNTA (0.71) | FNTAFNTBPGGT1BBCL2L1TDP1 | |
| SCHEMBL10018886 | 0.81 | FNTA (0.66) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL6774837 | 0.79 | FNTA (0.55) | FNTAFNTBPGGT1BBCL2L1TDP1 | |
| SCHEMBL16136628 | 0.77 | FNTA (0.71) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | claimed |
| US-6693123-B2 | (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA | UNIVERSITY OF PITTSBURGH | 2004-02-17 | — | — | US | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | FNTA 20/4885FNTB 2/4885PGGT1B 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.